Suppressive effect of YY1‑mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma

Cao,Shou-Ji; Ge,Wan-Li; Meng,Ling-Dong; Chen,Qun; Miao,Yi; Jiang,Kui-Rong; Zhang,Jing-Jing

doi:10.3892/ol.2022.13577

Suppressive effect of YY1‑mediated RGS22 regulation on the proliferation, migration and invasion of pancreatic ductal adenocarcinoma

Authors:
- Shou-Ji Cao
- Wan-Li Ge
- Ling-Dong Meng
- Qun Chen
- Yi Miao
- Kui-Rong Jiang
- Jing-Jing Zhang
View Affiliations

Affiliations: Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: November 2, 2022 https://doi.org/10.3892/ol.2022.13577
Article Number: 457
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Regulator of G‑protein signaling 22 (RGS22) is specifically expressed in the testis and in tumors of epithelial origin, but the expression and role of RGS22 in pancreatic cancer are unclear. In this study, 52 pairs of pancreatic ductal adenocarcinoma (PDAC) and adjacent non‑neoplastic tissue samples with the corresponding clinical data were used to examine the expression of RGS22 and its relationship with PDAC prognosis. The findings showed that the expression of RGS22 was higher in the PDAC tissues than in the adjacent non‑tumorous tissues and its expression was associated with the degree of blood vessel invasion. The in vitro experiments with PDAC cell lines and a normal control cell line showed that the proliferation, invasion, and metastasis of PDAC cells were suppressed by RGS22 overexpression and enhanced by RGS22 knockdown. The in vivo effect of RGS22 on PDAC xenografts was studied using subcutaneous implantation of tumor cells in BALB/cA‑nu mice, and the results corroborated the in vitro findings. Analysis of the regulators of RGS22 showed that it was positively regulated by the transcription factor Yin Yang‑1 (YY1). Thus, YY1‑mediated RGS22 regulation suppressed the proliferation, migration, and invasion of PDAC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Griffin JF, Poruk KE and Wolfgang CL: Pancreatic cancer surgery: Past, present, and future. Chin J Cancer Res. 27:332–348. 2015.PubMed/NCBI
3	Dal Molin M, Zhang M, de Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B, Kinzler KW, Papadopoulos N, et al: Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: Results of whole-exome sequencing analysis. Clin Cancer Res. 21:1944–1950. 2015. View Article : Google Scholar : PubMed/NCBI
4	Chin V, Nagrial A, Sjoquist K, O'Connor CA, Chantrill L, Biankin AV, Scholten RJ and Yip D: Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane. Database Syst Rev. 3:CD0110442018.PubMed/NCBI
5	Grasso C, Jansen G and Giovannetti E: Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Crit Rev Oncol Hematol. 114:139–152. 2017. View Article : Google Scholar : PubMed/NCBI
6	Gordon S, Akopyan G, Garban H and Bonavida B: Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene. 25:1125–1142. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shi Y, Lee JS and Galvin KM: Everything you have ever wanted to know about Yin Yang 1. Biochim Biophys Acta. 1332:F49–F66. 1997.PubMed/NCBI
8	Shi Y, Seto E, Chang LS and Shenk T: Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell. 67:377–388. 1991. View Article : Google Scholar : PubMed/NCBI
9	Thomas MJ and Seto E: Unlocking the mechanisms of transcription factor YY1: Are chromatin modifying enzymes the key? Gene. 236:197–208. 1999. View Article : Google Scholar : PubMed/NCBI
10	Zhang JJ, Zhu Y, Xie KL, Peng YP, Tao JQ, Tang J, Li Z, Xu ZK, Dai CC, Qian ZY, et al: Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism. Mol Cancer. 13:1302014. View Article : Google Scholar : PubMed/NCBI
11	Yang C, Zhang JJ, Peng YP, Zhu Y, Yin LD, Wei JS, Gao WT, Jiang KR and Miao Y: A Yin-Yang 1/miR-30a regulatory circuit modulates autophagy in pancreatic cancer cells. J Transl Med. 15:2112017. View Article : Google Scholar : PubMed/NCBI
12	Koelle MR: A new family of G-protein regulators-the RGS proteins. Curr Opin Cell Biol. 9:143–147. 1997. View Article : Google Scholar : PubMed/NCBI
13	Siderovski DP, Hessel A, Chung S, Mak TW and Tyers M: A new family of regulators of G-protein-coupled receptors? Curr. Biol. 6:211–212. 1996.PubMed/NCBI
14	Watson N, Linder ME, Druey KM, Kehrl JH and Blumer KJ: RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits. Nature. 383:172–175. 1996. View Article : Google Scholar : PubMed/NCBI
15	Hunt TW, Fields TA, Casey PJ and Peralta EG: RGS10 is a selective activator of G alpha i GTPase activity. Nature. 383:175–177. 1996. View Article : Google Scholar : PubMed/NCBI
16	Hu Y, Xing J, Wang L, Huang M, Guo X, Chen L, Lin M, Zhou Y, Liu Z, Zhou Z and Sha J: RGS22, a novel cancer/testis antigen, inhibits epithelial cell invasion and metastasis. Clin Exp Metastasis. 28:541–549. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hu Y, Xing J, Chen L, Guo X, Du Y, Zhao C, Zhu Y, Lin M, Zhou Z and Sha J: RGS22, a novel testis-specific regulator of G-protein signaling involved in human and mouse spermiogenesis along with GNA12/13 subunits. Biol Reprod. 79:1021–1029. 2008. View Article : Google Scholar : PubMed/NCBI
18	Hu Y, Xing J, Chen L, Zheng Y and Zhou Z: RGS22 inhibits pancreatic adenocarcinoma cell migration through the G12/13 α subunit/F-actin pathway. Oncol Rep. 34:2507–2514. 2015. View Article : Google Scholar : PubMed/NCBI
19	Kamarajah SK, Burns WR, Frankel TL, Cho CS and Nathan H: Validation of the American joint commission on cancer (AJCC) 8th edition staging system for patients with pancreatic adenocarcinoma: A surveillance, epidemiology and end results (SEER) analysis. Ann Surg Oncol. 24:2023–2030. 2017. View Article : Google Scholar : PubMed/NCBI
20	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
21	Sriram K and Insel PA: G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs? Mol Pharmacol. 93:251–258. 2018. View Article : Google Scholar : PubMed/NCBI
22	Wang D, Xu Y, Feng L, Yin P, Song SS, Wu F, Yan P and Liang Z: RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia. Oncol Rep. 41:165–177. 2019.PubMed/NCBI
23	O'Brien JB, Wilkinson JC and Roman DL: Regulator of G-protein signaling (RGS) proteins as drug targets: Progress and future potentials. J Biol Chem. 294:18571–18585. 2019. View Article : Google Scholar : PubMed/NCBI